TTIPF (TTIPF)
OTC Markets OTCQX
Fundamentals
Valuation and ratings
TTIPF trades at USD0.42. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About TTIPF
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
The full research page for TTIPF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.